Skip Navigation


Cardiovascular Research Advance Access originally published online on January 31, 2008
Cardiovascular Research 2008 78(3):429-439; doi:10.1093/cvr/cvn018
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
78/3/429    most recent
cvn018v2
cvn018v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Cardiovasc Res
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hans, C. P.
Right arrow Articles by Boulares, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hans, C. P.
Right arrow Articles by Boulares, A. H.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Differential effects of PARP inhibition on vascular cell survival and ACAT-1 expression favouring atherosclerotic plaque stability

Chetan P. Hans, Mourad Zerfaoui, Amarjit S. Naura, Andrew Catling and A. Hamid Boulares*

Department of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center, 1901 Perdido St., New Orleans, LA 70112, USA

* Corresponding Author. Tel: +1 504 568 2304; fax: +1 504 568 2361. E-mail address: hboulr{at}lsuhsc.edu

Aims: The aim of this study was to take a combination of animal and cell culture approaches to examine the individual responses of vascular cells to varying inflammatory factors in order to gain insights on the mechanism(s) by which poly(ADP-ribose) polymerase (PARP) inhibition promotes factors of plaque stability.

Methods and results: Apolipoprotein (ApoE–/–) mice fed a high-fat diet were used as a model of atherosclerosis. Primary endothelial cells, smooth muscle cells (SMCs), and ex-vivo generated foam cells (FCs) were used in our in vitro studies. PARP inhibition significantly decreased the markers of oxidative stress and caspase-3 activation and increased smooth muscle actin within plaques from ApoE–/– mice fed a high-fat diet. PARP inhibition protected against apoptosis and/or necrosis in SMCs and endothelial cells in response to H2O2 or tumour necrosis factor (TNF). Remarkably, PARP inhibition in FCs resulted in significant sensitization to 7-ketocholesterol (7-KC) by increasing cellular-toxic-free cholesterol, potentially through a down-regulation of acyl-CoA:cholesterol acyltransferase-1 (ACAT-1) expression. 7-KC induced necrosis exclusively in endothelial cells, which was, surprisingly, unaffected by PARP inhibition indicating that PARP inhibition does not prevent all forms of necrotic cell death. In SMCs, PARP-1 inhibition by gene deletion conferred protection against 7-KC or TNF, potentially by reducing caspase-3-like activation, preventing induction of c-Jun N-terminal protein kinase phosphorylation, and inducing extracellular signal-regulated kinase phosphorylation independently of PARP classical enzymatic activity.

Conclusions: These data present PARP-1 as an important player in the death of cells constituting atherosclerotic plaques contributing to plaque dynamics. PARP inhibition may be a protective, a neutral, or a sensitizing factor. Additionally, PARP-1 may be a novel factor that can alter lipid metabolism. These novel functions of PARP not only challenge the current understanding of the role of the enzyme in cell death but also provide insights on the intricate contribution of PARP in cellular responses to predominant inflammatory factors within atherosclerotic plaques, presenting additional evidence for the viability of PARP inhibition as a therapeutic strategy for atherosclerosis.

KEYWORDS Atherosclerosis; Apoptosis; Necrosis; PARP-1; Lipid metabolism


Time for primary review: 21 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Cardiovasc Res:

Targeting the prevention of plaque rupture as a new strategy for prevention of acute arterial cardiovascular events
Marcel Levi and Erik Stroes
Cardiovasc Res 2008 78: 407-408. [Extract] [FREE Full Text]  

Related Article

Targeting the prevention of plaque rupture as a new strategy for prevention of acute arterial cardiovascular events
Marcel Levi and Erik Stroes
Cardiovasc Res 2008 78: 407-408. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
C. P. Hans, M. Zerfaoui, A. S. Naura, D. Troxclair, J. P. Strong, K. Matrougui, and A. H. Boulares
Thieno[2,3-c]Isoquinolin-5-one, a Potent Poly(ADP-Ribose) Polymerase Inhibitor, Promotes Atherosclerotic Plaque Regression in High-Fat Diet-Fed Apolipoprotein E-Deficient Mice: Effects on Inflammatory Markers and Lipid Content
J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 150 - 158.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Levi and E. Stroes
Targeting the prevention of plaque rupture as a new strategy for prevention of acute arterial cardiovascular events
Cardiovasc Res, June 1, 2008; 78(3): 407 - 408.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.